Modern cancer control is shifting from reactive, late-stage treatment toward proactive, upstream prevention, according to researchers at the World Health Organization’s (WHO) International Agency for Research on Cancer (IARC). By targeting viral-related cancers—specifically those linked to human papillomavirus (HPV) and Epstein-Barr virus (EBV)—health systems can utilize vaccines and early detection to reduce global mortality, though progress remains hampered by significant geographic and economic inequalities.
HPV Vaccination Gaps and the Path to Elimination
The global burden of cervical cancer remains immense, with the WHO reporting approximately 662,000 new cases and 349,000 deaths in 2022. Because persistent infection with oncogenic HPV types causes nearly all cervical cancers, the virus serves as a primary target for public health intervention. To lower barriers to entry, the WHO updated its guidance to support a single-dose vaccine schedule, a move designed to reduce logistical costs and improve coverage.
Despite these efforts, systemic inequality prevents widespread success. According to the WHO, 94% of cervical cancer deaths occur in low- and middle-income countries (LMICs). While 70% of upper-middle-income nations have integrated the HPV vaccine into their national immunization schedules, only 31% of non-Gavi lower-middle-income countries had done so by 2022. Achieving the WHO’s 2030 goal—90% vaccination coverage by age 15 and 70% screening coverage—requires overcoming these stark disparities in access.
Did you know? In 2021, only about 15% of eligible girls worldwide had completed the recommended two-dose HPV vaccination series, highlighting a massive gap between clinical potential and real-world implementation.
EBV: Targeting the Next Prevention Frontier
Unlike HPV, which benefits from established, licensed vaccines, Epstein-Barr virus (EBV) presents a different challenge: the need for foundational evidence to support future interventions. EBV is linked to several malignancies, including nasopharyngeal carcinoma, Hodgkin lymphoma, and specific gastric cancers. In 2022, nasopharyngeal cancer alone accounted for over 120,000 new cases globally, predominantly in East and Southeast Asia.
Recent research is moving the field toward predictive, actionable strategies. A 2025 study published in Nature Communications found that testing for EBV viral capsid antigen immunoglobulin A in prospective cohorts in southern China successfully identified increased risk for multiple cancers. Furthermore, combining this serology with polygenic risk scores offers a potential roadmap for personalized screening. By identifying high-risk populations before symptoms emerge, researchers hope to lay the groundwork for future vaccines and early-intervention therapies.
Risk-Based Screening and Multi-Disciplinary Policy
The future of cancer prevention lies in integrating multi-disciplinary data—connecting epidemiology, laboratory diagnostics, and implementation science. For cervical cancer, the European Commission Initiative on Cervical Cancer has introduced updated recommendations that prioritize a risk-based approach. These strategies specifically tailor screening intervals for populations already vaccinated against HPV, moving away from “one-size-fits-all” testing.
This transition toward precision prevention allows health ministries to allocate resources more efficiently. By monitoring where prevention efforts are succeeding versus where they are failing, policymakers can better direct financial and political commitments. The goal is to move beyond merely demonstrating causation and toward creating sustainable systems that account for local risk profiles and economic realities.
Pro Tip: For clinicians and policymakers, the focus is shifting from broad population screening to stratified risk assessment. Utilizing longitudinal cohort data—like that currently shaping EBV policy—is essential for designing the next generation of targeted cancer prevention tools.
Frequently Asked Questions
Why is there a shift toward single-dose HPV vaccines?
The WHO recommends a single-dose schedule to simplify logistics, lower costs, and increase vaccination rates, particularly in resource-limited settings where two-dose completion is difficult to achieve.
Is there a vaccine for EBV?
Currently, there is no licensed cancer-preventing vaccine for EBV. However, several candidates are in development or early-phase clinical trials, supported by ongoing research into risk stratification.
What are the primary goals of the WHO’s 2030 cervical cancer strategy?
The strategy aims for 90% vaccination coverage for girls by age 15, 70% screening coverage, and 90% access to treatment for women with pre-cancer or invasive cervical cancer.
Are you interested in how public health policy is reshaping cancer care in your region? Explore our archives on global health initiatives or subscribe to our newsletter for the latest updates on medical research and policy developments.
